It belongs to a novel class of agents known as triple receptor agonists , meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1) which reduces appetite and slows gastric emptying [7] [8] GIP (glucose-dependent insulinotropic polypeptide) which is hypothesised to enhance insulin secretion and may play a role in fat metabolism, though the precise contribution remains under investigation Glucagon receptor which is thought to increase energy expenditure and promote hepatic fat breakdown, though these mechanisms are still being characterised in human studies [9] [10] This triple mechanism distinguishes retatrutide from existing approved agents such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GLP-1/GIP agonist), and is thought to produce more pronounced effects on body weight
Mixing Adderall and Xanax can result in an increased risk of overdose and addiction
The basics: GLP1 receptor agonists and the future of anti-obesity drugs GLP1 is a specific gut hormone called an incretin which is made by cells (called L cells) that line the small intestine
Body aches on tirzepatide are caused by indirect effects including dehydration, electrolyte imbalances, rapid weight loss, and muscle-related nutritional deficiencies
This central action drastically decreases sympathetic outflow from the central nervous system to the heart, kidneys, and peripheral vasculature (Figure 1)(Patel and Saadabadi, 2025)
The extent of improvement was similar between experimental groups for all outcome measures analysed [55]
